Theralase Technologies Inc. (CVE:TLT – Get Free Report) traded up 2.9% on Wednesday . The company traded as high as C$0.18 and last traded at C$0.18. 61,000 shares were traded during trading, a decline of 48% from the average session volume of 117,903 shares. The stock had previously closed at C$0.18.
Theralase Technologies Stock Performance
The company has a debt-to-equity ratio of 14.85, a quick ratio of 3.40 and a current ratio of 1.91. The firm has a 50 day moving average price of C$0.24 and a two-hundred day moving average price of C$0.25. The company has a market capitalization of C$43.83 million, a P/E ratio of -9.59 and a beta of 1.36.
Theralase Technologies Company Profile
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
See Also
- Five stocks we like better than Theralase Technologies
- How to Invest in Blue Chip Stocks
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- Insider Buying Explained: What Investors Need to Know
- The 3 Most Talked About Investments on WallStreetBets Right Now
- Are Penny Stocks a Good Fit for Your Portfolio?
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
